PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has completed the inclusion of patients in its phase I/II study of its lead candidate PC-A11 in cancer patients.
The last patient has been treated with the company's proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin at University College Hospital (UCH) in London.
Principal Investigator, Colin Hopper said: "We at UCH are proud of being the first in the world to use the PCI technology in the treatment of cancer patients. The results have been very positive, with strong tumour response in all the treated patients, and we look forward to take part in the further development of PC-A11 in the treatment of Head and Neck cancer patients."
Per Walday, CEO of PCI Biotech said: "We are very happy to have completed the inclusion of patients in the PC-A11 phase I/II study. This study has proved that we can transfer strong preclinical results to equally strong clinical results, and this is promising for the further development of PC-A11 and other combination products based on the PCI technology platform."
A total of 19 cancer patients have been treated in the phase I/II study of PC-A11. Reference is made to PCI Biotech's Q4 2010 report for a summary of the results from the first 14 patients. Complete results from the last 5 patients will be published as soon as all these patients have finished the 3 months follow up.
Breakthrough imaging method enhances precision in prostate cancer treatment